Company: STAA
Filing Date: 2025-10-27
Form Type: PX14A6G
Source: 0001193125-25-250625
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-27
Form: PX14A6G
Chunk 1
---
 text of the letter to the Board is as follows:

October 25, 2025

STAAR Surgical Company

25510 Commercentre Drive

Lake Forest, CA 92630

Dear Members of the Board:

We are writing to express our
disappointment over the Board’s decision to adjourn the Special Meeting of Stockholders until November 6, 2025. Extending the timeline prolongs uncertainty about STAAR’s future and delays the Board and management team from
implementing a clear strategy to accelerate the Company’s momentum, particularly in its largest market of China.

We are also concerned that the
Board and Alcon did not communicate a reason for the adjournment. That makes us worry they will use the time window created by this adjournment to amend the existing merger agreement in some manner to try and appear proactive and appeal to
shareholders. We believe such efforts would be illusory and would not address any of the fundamental concerns we and other shareholders have been voicing since announcement, and we remind the Company that shareholders will not be appeased by such
desperate measures.

Continuing a process while Alcon’s opportunistic $28 per share offer remains outstanding will act as a deterrent for new
bidders, and will taint the bidding process. In our view, running a rushed sales process from a position of weakness is unlikely to yield credible interest that offers fair value for STAAR. The Company’s negotiating power would inevitably be
impacted by the low, baseline reference point of Alcon’s $28 offer and its predatory terms. Furthermore, based on recent disclosures of the Company, we believe certain members of the Board and management team are conflicted in light of the
Alcon transaction and should not be involved in seeking competing offers.

If the Board is serious about securing fair value for shareholders, it should wait until the merger
agreement with Alcon is ended and then initiate a disciplined strategic alternatives review at an appropriate time and from a position of strength. Not when it’s best for counterparties, but when it’s best for STAAR. We believe this new
process should include a comprehensive market canvass, provide potential counterparties sufficient time to conduct due diligence, and actively engage both strategic buyers and financial sponsors.

Based on our most recent on-the-ground analysis, the market conditions for ICL
in China are continuing to improve, which demonstrates increased demand from STAAR’s end customers. We estimate that STAAR is seeing double-digit end demand growth in China during the last couple of